Wave Life Sciences, Inc. (WVE): R&D Expense
$182.78M
Year ended 2025-12-31
$197.42M
Trailing 12 months to 2026-06-30
+16.4%
3-year compound annual growth
+6.9%
5-year compound annual growth
+35.0%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $182.78M | +14.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $159.68M | +22.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $130.01M | +12.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $115.86M | -4.9% | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | $121.88M | -6.9% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $130.94M | -25.4% | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | $175.43M | +30.5% | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | $134.43M | +69.5% | 2020-03-02, From 2018-01-01 |
| 2017-12-31 | $79.31M | +94.3% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $40.82M | +350.7% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $9.06M | +278.2% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $2.40M | +24.7% | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | $1.92M | n/a | 2016-03-30, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $182.78M | +14.5% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $56.04M | +36.0% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $3.72M | +78.0% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $5.57M | +15.6% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $17.19M | -15.2% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $97.58M | +49.4% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $159.29M | +15.3% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $672.7K | -50.6% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
Compare WVE, XLO, BFRI, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗